IO102

BIOLOGICAL2 trials

Sponsors

IO Biotech, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions

Hypopharynx Squamous Cell CarcinomaLarynx Squamous Cell CarcinomaNSCLCOral Cavity Squamous Cell CarcinomaOropharynx Squamous Cell Carcinoma

Phase 1

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

CompletedNCT03562871

IO BiotechNSCLC

Start: 2018-08-22End: 2022-04-12Updated: 2022-04-21

Phase 2

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

TerminatedNCT04445064

Cliniques universitaires Saint-Luc- Université Catholique de LouvainHypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma +1

Start: 2020-08-14End: 2025-03-20Updated: 2025-12-16